There is a need for improvement of thyrotropin measurements in the clinical laboratory, specifically in the lower portion of the normal range. We cite realistic examples of incorrect, misleading data generated with many thyrotropin kits currently in use and propose a practical laboratory protocol to evaluate the performance of a procedure for determining thyrotropin.
It is our opinion that most commercial thyrotropin kits currently in use for the measurement of thyrotropin Clinical chemists and pathologists strive for analytical sensitivity and specificity in an assay to assure precision and accuracy, as does the analytical chemist. We do not believe that these goals have been attained with most of the thyrotropin kits currently in use.
Most thyrotropin kits appear to have difficulty measuring correctly in the low end of the normal range, because of the lack of analytical sensitivity and analytical specificity and because of a matrix effect that causes spurious intrinsic differences between the standards and the patients' specimens. The matrix effect can lead to either positive or negativeerrors. The lackofanalytical sensitivity can leadto poor reproducibility (precision), and the lack of analytical specificity, to falsely increased values. An example will illustrate the significance of the clinical effect of these three parameters. What does a physician do when he receives a laboratory report with a free thyroxin (FF4) of 44 ng/L (normal 8-19) and a thyrotropin of 4.8 milli-int. units/L (normal 0-9.0), for a patient who gives the clinical impression of hyperthyroidism?
If the physician is an endocrinologist, he probably concludes that there is no further concern for the patient because thyrotropin-secret- (1) (2) (3) (4) . Obviously, these data for thyrotropin are based on research radioimmunoassay methods, which require several days of incubation to reach equilibrium and attain the high sensitivity and specificity inherent in such methods.
We, as clinical chemists and pathologists, use several criteria in evaluating a new kit or procedure. results. In the case of thyrotropin, however, there is no guarantee that the standard procedures cited above, and the variations thereof, will provide a laboratory with an accurate and precise thyrotropin kit. Thyrotropin kits cannot be evaluated in the same way kits for many other analytes are evaluated.
Therefore, we have added several additional criteria for proper evaluation of thyrotropin kits, integrating the requirements of analytical sensitivity and analytical specificity with clinical analytical data and basic physiology: #{149} The matrix effect can easily be evaluated by analyzing different types of serum, such as bovine, equine, and "stripped" human serum, undiluted and diluted with saline. The results should be equivalent to the zero thyrotropin standard if there is no matrix effect. The most rigorous test is to analyze water as a sample; ideally, the water sample will yield results equivalent to those of the zero standard. This ideal is generally difficult to attain. The closer to the zero standard, the less the matrix effect (within the sensitivity of the method).
#{149}
The analytical sensitivity can be evaluated by analyzing the zero standard in replicate (20 times) and determining the two standard deviation (2 SD) value. This value, also referred to as the minimum detectable dose, should be as small as possible and at least <0.5 milli-int.
unit/L for thyrotropin.
The clinical significance and importance of knowing the sensitivity of a method can be seen in a patient for whom the serum thyrotropin concentration is "undetectable." If the sensitivity is 0.5 milli-int. unitiL, "undetectable" means that the patient's result, as read from a standard curve or calculated by a computer, is 0 ± 0.5 milli-int. unit/L. This information can be diagnostically useful in hyperthyroidism and in hypothalamic or pituitary hypothyroidism. Sensitivity is also an important factor affecting the reproducibility (precision) of the method, especially in the low normal range. A control specimen with a mean value of approximately 1.0 milli-int. unitJL should be evaluated and included in each analytical series of patients' samples, in addition to other controls. At this value for the control, a 2 SD of 0.3 milli-int. unitlL and a CV of 15 to 20% are acceptable.
The analytical specificity can be evaluated in several ways: (a) a serum or the zero standard can be supplemented with known amounts of known cross reactants, the specimens analyzed for thyrotropmn, and the cross reactivity valuescalculated; or(b) a more expeditious procedure can be used, exploitingbasic endocrine physiology. The pituitary hormones thyrotropin (TSH), lutropin (LH), and follitropin (FSH) and the placental hormone choriogonadotropin (CG) each have two polypeptide chains, designated the alpha and beta subunits. The alpha subunits of these hormones are structurally and immunologically similar. The beta subunits are structurally and immunologically distinct, and confer biological specificity to the respective hormones (5).
Moreover, in pregnant women, the concentration of choriogonadotropin in serum is greatest in the eighth to twelfth weeks of gestation (100 to 150 kilo-mt. units/L). Antibodies used in the various thyrotropin kits are raised and purified for specificity to the thyrotropin beta subunit; thus, given the similarity of the alpha subunits of the above-mentioned hormones, using the thyrotropin kit in question for analysis of serum from pregnant women with high concentrations of We therefore recommend that in evaluating a thyrotropin procedure certain additional criteria should be included in the technical evaluation protocol to assure analytical accuracy.
Let us remember that there is no such thing as a "simple blood test" in the clinical laboratory; science and technology only make it appear so. We, as clinical scientists, should always integrate the physiological concept with the analytical result!
